Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use
CONCLUSIONS: We describe the reduction in the number of patients with dispensed antibiotics and antibiotic consumption after the COVID-19 lockdown persisted in a period of recovery of healthcare accessibility. This information may help to improve antimicrobial use at the primary care level.PMID:38465485 | DOI:10.1080/14787210.2024.2328333 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 11, 2024 Category: Infectious Diseases Authors: Thais de Pando Santiago Grau Alexander Almendral Daniel Echeverr ía-Esnal Sergi Hern ández Enric Limon Caridad Pontes Source Type: research

Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use
CONCLUSIONS: We describe the reduction in the number of patients with dispensed antibiotics and antibiotic consumption after the COVID-19 lockdown persisted in a period of recovery of healthcare accessibility. This information may help to improve antimicrobial use at the primary care level.PMID:38465485 | DOI:10.1080/14787210.2024.2328333 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 11, 2024 Category: Infectious Diseases Authors: Thais de Pando Santiago Grau Alexander Almendral Daniel Echeverr ía-Esnal Sergi Hern ández Enric Limon Caridad Pontes Source Type: research

Personalized care approaches to hepatitis C therapy: recent advances and future directions
Expert Rev Anti Infect Ther. 2024 Mar 11:1-13. doi: 10.1080/14787210.2024.2328336. Online ahead of print.ABSTRACTINTRODUCTION: The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further improvement in optimizing therapy efficacy and minimizing adverse effects.AREAS COVERED: This review is devoted to the rationale for adopting a personalized approach to HCV therapy. Specifically, we explore the role of host-related factors, such as sex or the presence of comorbidities. We thoroughly examin...
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Nicola Schiano Moriello Biagio Pinchera Ivan Gentile Source Type: research

Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
CONCLUSIONS: The bismuth add-on increased the first-line H. pylori eradication rate of 2-week TPZ-based triple therapy.PMID:38459869 | DOI:10.1080/14787210.2024.2329251 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Jun-Hyung Cho Source Type: research

Personalized care approaches to hepatitis C therapy: recent advances and future directions
Expert Rev Anti Infect Ther. 2024 Mar 8. doi: 10.1080/14787210.2024.2328336. Online ahead of print.ABSTRACTINTRODUCTION: The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further improvement in optimizing therapy efficacy and minimizing adverse effects.AREAS COVERED: This review is devoted to the rationale for adopting a personalized approach to HCV therapy. Specifically, we explore the role of host-related factors, such as sex or the presence of comorbidities. We thoroughly examine the ...
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Nicola Schiano Moriello Biagio Pinchera Ivan Gentile Source Type: research

Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
CONCLUSIONS: The bismuth add-on increased the first-line H. pylori eradication rate of 2-week TPZ-based triple therapy.PMID:38459869 | DOI:10.1080/14787210.2024.2329251 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 9, 2024 Category: Infectious Diseases Authors: Jun-Hyung Cho Source Type: research

Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.PMID:38457124 | DOI:10.1080/14787210.2024.2326561 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Behnam Amani Bahman Amani Source Type: research

Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning
Expert Rev Anti Infect Ther. 2024 Mar 8:1-9. doi: 10.1080/14787210.2024.2322445. Online ahead of print.ABSTRACTINTRODUCTION: Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the management of febrile neutropenia (FN) and drive progress toward personalized medicine.AREAS COVERED: In this review, we detail how the collection of a large number of high-quality data can be used to conduct precise mathematical studies with ML and AI. We explain the foundations of these techniques, covering the fundamentals of supervised and unsupervised learning, as well as the most important challenges,...
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Antonio Gallardo-Pizarro Olivier Peyrony Mariana Chumbita Patricia Monzo-Gallo Tommaso Francesco Aiello Christian Teijon-Lumbreras Emmanuelle Gras Josep Mensa Alex Soriano Carolina Garcia-Vidal Source Type: research

Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.PMID:38457124 | DOI:10.1080/14787210.2024.2326561 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Behnam Amani Bahman Amani Source Type: research

Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning
Expert Rev Anti Infect Ther. 2024 Mar 8:1-9. doi: 10.1080/14787210.2024.2322445. Online ahead of print.ABSTRACTINTRODUCTION: Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the management of febrile neutropenia (FN) and drive progress toward personalized medicine.AREAS COVERED: In this review, we detail how the collection of a large number of high-quality data can be used to conduct precise mathematical studies with ML and AI. We explain the foundations of these techniques, covering the fundamentals of supervised and unsupervised learning, as well as the most important challenges,...
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Antonio Gallardo-Pizarro Olivier Peyrony Mariana Chumbita Patricia Monzo-Gallo Tommaso Francesco Aiello Christian Teijon-Lumbreras Emmanuelle Gras Josep Mensa Alex Soriano Carolina Garcia-Vidal Source Type: research

Comparing prolonged infusion to intermittent infusion strategies for beta-lactam antibiotics in patients with gram-negative bacterial infections: a systematic review and meta-analysis
CONCLUSIONS: The PI approach for administering beta-lactam antibiotics in patients with suspected or confirmed GNB infections may be advantageous in reducing mortality rates and the duration of MV when compared to the II strategy.PMID:38441052 | DOI:10.1080/14787210.2024.2324940 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 5, 2024 Category: Infectious Diseases Authors: Chih-Chung Lin Jheng-Yen Wu Po-Yu Huang Hui-Lin Sung Yu-Chun Tung Chih-Cheng Lai Yu-Feng Wei Pin-Kuei Fu Source Type: research